Ablynx and reMYND settle dispute amicably

2 June 2010 – Ablynx NV [Euronext Brussels: ABLX] and reMYND NV announced that they have reached a settlement concerning a dispute relating to a collaboration agreement to discover and commercialize new Nanobodies® which Ablynx and reMYND entered into in 2003. In 2007, Ablynx was notified by reMYND that a difference of interpretation existed in respect of Ablynx's contractual obligation to reMYND under the 2003 agreement.

Under this agreement, Ablynx had the obligation to pay reMYND 50% of any income received if certain Nanobodies from the above collaboration were licensed to a third party for development and commercialization. Ablynx has a collaboration with Boehringer Ingelheim in the area of Alzheimer’s disease with a potential deal value of $265 million plus royalties, under which, at this time, it believes, in contrast to reMYND, that no license to develop or commercialize any of the aforementioned Nanobodies has been granted... [PDF] reMYND's Press Release - Ablynx's newsroom -

Boehringer Ingelheim and Vitae Pharmaceuticals : a major collaboration to research and develop novel treatments for Alzheimer`s disease

15 June 2009 - Boehringer Ingelheim and Vitae Pharmaceuticals, Inc., announced that they have entered into a significant worldwide collaboration to research and develop beta-secretase (BACE) inhibitors for the treatment of Alzheimer’s disease. Current therapies for Alzheimer’s disease can improve symptoms, but do not affect the progression of the disease. The inhibition of BACE - an enzyme involved in the formation of amyloid-beta plaques which accumulate in the brains of patients with Alzheimer’s disease - offers the potential to slow or even halt disease progression.

...



Vitae Pharmaceuticals
Vitae Pharmaceuticals is an emerging pharmaceutical company building a clinical stage pipeline of novel drug candidates in important therapeutic categories, such as cardiovascular disease, diabetes and Alzheimer’s disease...

...



Boehringer Ingelheim
The Boehringer Ingelheim group is one of the world’s 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 138 affiliates in 47 countries and 41,300 employees. Since it was founded in 1885, the family-owned company has been committed to researching, developing, manufacturing and marketing novel products of high therapeutic value for human and veterinary medicine... Boehringer Ingelheim's Press Release - [PDF] Vitae Pharmaceuticals' Press Release -

Ablynx : BOEHRINGER INGELHEIM EXTENDS RESEARCH COLLABORATION WITH ABLYNX FOR ALZHEIMER'S DISEASE

21 August 2008 ­ - Ablynx [Euronext Brussels: ABLX], a pioneer in the discovery and development of Nanobodies, a novel class of antibodyderived therapeutic proteins, announced that the Alzheimer’s disease collaboration with Boehringer Ingelheim was proceeding well and therefore the research funding has been extended for another year.


In January 2007 Boehringer Ingelheim and Ablynx announced that they had entered into a $265 million worldwide research and licensing agreement to discover and develop new therapies for Alzheimer’s disease using Ablynx’s Nanobodies ® , a novel class of therapeutic proteins. The deal also included a joint research programme with Ablynx scientists. Boehringer Ingelheim will be solely responsible for the development, manufacture and commercialization of any products resulting from the collaboration. As part of the collaboration, Ablynx received an upfront fee and will receive development and commercial milestones as well as undisclosed royalties based on net sales... [PDF] Ablynx's Press Release -